357 related articles for article (PubMed ID: 17128524)
1. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
[TBL] [Abstract][Full Text] [Related]
2. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
[TBL] [Abstract][Full Text] [Related]
3. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
4. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
6. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
10. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
11. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
12. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
[TBL] [Abstract][Full Text] [Related]
15. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
17. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
18. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
19. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ;
J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264
[TBL] [Abstract][Full Text] [Related]
20. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H
J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
